Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema in Children and Adolescents With Overweight or Obesity
NCT07253285Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Jan 2026
- Primary completion
- Mar 2030
- Modality
- Peptides, Small Molecules
- Countries
- 26
01
Overview
A Phase 3 trial of cagrilintide in obesity, sponsored by Novo Nordisk. Started Jan 2026; status: recruiting.
02
Drugs
cagrilintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07253285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07253285.